Insider · CIK 0001709415

Sapir Alex

Reports to the SEC for 3 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001709415

Forms 4 and 5

Insider transactions

16 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-02	FULCFulcrum Therapeutics, Inc. · Stock option - Right to BuyA Award	Director, See Remarks	AAward	+650K sh	—	—	650,000
2025-01-24	FULCFulcrum Therapeutics, Inc. · Stock option - Right to BuyA Award	Director, See Remarks	AAward	+582K sh	—	—	582,000
2024-07-03	FULCFulcrum Therapeutics, Inc.M Exercise/Conversion	Director, See Remarks	MExercise/Conversion	+150K sh	$3.27	+$491K	193,360
2024-07-03	FULCFulcrum Therapeutics, Inc. · Stock option - Right to BuyM Exercise/Conversion	Director, See Remarks	MExercise/Conversion	−150K sh	—	—	2,280,400
2024-03-04	FULCFulcrum Therapeutics, Inc.P Purchase	Director, See Remarks	PPurchase	+43.4K sh	$11.35	+$492K	43,360
2023-05-19	PhaseBio Pharmaceuticals IncM Exercise/Conversion	Director	MExercise/Conversion	+3,750 sh	—	—	3,750
2023-05-19	PhaseBio Pharmaceuticals IncRestricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,750 sh	—	—	0
2022-05-19	PhaseBio Pharmaceuticals IncNon-employee Director Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2022-05-19	PhaseBio Pharmaceuticals IncRestricted Stock UnitsA Award	Director	AAward	+3,750 sh	—	—	3,750
2021-06-03	PhaseBio Pharmaceuticals IncNon-employee Director Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000
2020-06-03	PhaseBio Pharmaceuticals IncNon-employee Director Stock Option (right to buy)A Award	Director	AAward	+4,909 sh	—	—	4,909
2020-02-12	PhaseBio Pharmaceuticals IncEmployee Stock Option (right to buy)A Award	Director	AAward	+32K sh	—	—	32,000
2018-08-14	Dova Pharmaceuticals Inc.P Purchase	Director, President & CEO	PPurchase	+21.7K sh	$22.83	+$495K	21,700
2017-12-22	Dova Pharmaceuticals Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+26.8K sh	$3.73	+$100K	46,909
2017-12-22	Dova Pharmaceuticals Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−26.8K sh	—	—	887,291
2017-07-05	Dova Pharmaceuticals Inc.P Purchase	Director, President & CEO	PPurchase	+20.1K sh	$17.00	+$342K	20,100

Recent filings

Accepted (ET)
Feb 44
Sapir Alex0001193125-26-037572
SEC(opens sec.gov)
Jan 284
Sapir Alex0000950170-25-009816
SEC(opens sec.gov)
Jul 84
Sapir Alex0000950170-24-081949
SEC(opens sec.gov)
Mar 54
Sapir Alex0000950170-24-025933
SEC(opens sec.gov)
May 194
Sapir Alex0001169245-23-000029
SEC(opens sec.gov)
May 204
Sapir Alex0001169245-22-000063
SEC(opens sec.gov)
Jun 44
Sapir Alex0001169245-21-000064
SEC(opens sec.gov)
Jun 54
Sapir Alex0001169245-20-000057
SEC(opens sec.gov)
Feb 144
Sapir Alex0001169245-20-000030
SEC(opens sec.gov)
Aug 154
Sapir Alex0001209191-18-046800
SEC(opens sec.gov)
Dec 274
Sapir Alex0001209191-17-067415
SEC(opens sec.gov)
Jul 74
Dova Pharmaceuticals, Inc.0001209191-17-044261
SEC(opens sec.gov)

Companies

Address

C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET

CAMBRIDGE, MA, 02139